MRK - Merck & Co., Inc.

NYSE - NYSE Delayed price. Currency in USD
76.25
-0.62 (-0.81%)
At close: 4:02PM EDT

79.10 +2.85 (3.74%)
Pre-market: 7:42AM EDT

Stock chart is not supported by your current browser
Previous close76.87
Open76.28
Bid77.98 x 1200
Ask79.16 x 800
Day's range75.32 - 77.44
52-week range65.25 - 92.64
Volume9,181,539
Avg. volume13,796,579
Market cap193.391B
Beta (5Y monthly)0.69
PE ratio (TTM)20.01
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield2.44 (3.17%)
Ex-dividend date12 Mar 2020
1y target estN/A
  • Coronavirus fears sparks market swings
    Yahoo Finance Video

    Coronavirus fears sparks market swings

    Yahoo Finance's Anjalee Khemlani outlines market risk as coronavirus fears continue to spook investors.

  • Reuters

    Merck KGaA to hold shareholder meeting online, confirms dividend

    Drugs and chemicals maker Merck KGaA on Monday became the second German blue-chip company to move its annual shareholders' meeting online after the government laid the ground for such a switch last week. "Merck will seize the opportunity created by legislators to hold the 2020 annual general meeting in a virtual format - not least to allow for a payout to shareholders of the dividend that was proposed for the 2019 business year as soon as possible," a spokesman told Reuters. Merck earlier this month proposed https://www.merckgroup.com/investors/reports-and-financials/earnings-materials/2019-q4/en/2019-Q4-Press-Release-EN.pdf a dividend of 1.30 euros ($1.44) per share.

  • J&J's Chief Scientific Officer predicts vaccinations against coronavirus within 12 months
    Yahoo Finance

    J&J's Chief Scientific Officer predicts vaccinations against coronavirus within 12 months

    Johnson & Johnson Chief Scientific Officer Dr. Paul Stoffels predicts the most vulnerable will begin to receive vaccines within 12 months to prevent COVID-19.

  • The Zacks Analyst Blog Highlights: Pfizer, Roche, Sanofi, Lilly and Merck
    Zacks

    The Zacks Analyst Blog Highlights: Pfizer, Roche, Sanofi, Lilly and Merck

    The Zacks Analyst Blog Highlights: Pfizer, Roche, Sanofi, Lilly and Merck

  • Pharma Stock Roundup: SNY, RHHBY, PFE's Coronavirus Product Development & Other Updates
    Zacks

    Pharma Stock Roundup: SNY, RHHBY, PFE's Coronavirus Product Development & Other Updates

    Pfizer (PFE) is set to jointly develop BioNTech's potential coronavirus vaccine. Regeneron/Sanofi (SNY) and Roche will study their RA drugs, Kevzara & Actemra, respectively to treat severe COVID-19 infection.

  • AstraZeneca/Merck's Lynparza Combo Ovarian Cancer Study Fails
    Zacks

    AstraZeneca/Merck's Lynparza Combo Ovarian Cancer Study Fails

    AstraZeneca (AZN)/Merck's (MRK) study evaluating cediranib added to Lynparza fails to meet the primary endpoint of PFS in patients with platinum-sensitive relapsed ovarian cancer

  • Why It Might Not Make Sense To Buy Merck & Co., Inc. (NYSE:MRK) For Its Upcoming Dividend
    Simply Wall St.

    Why It Might Not Make Sense To Buy Merck & Co., Inc. (NYSE:MRK) For Its Upcoming Dividend

    Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

  • Merck KGaA forecasts strong profit growth on healthcare, lab gear
    Reuters

    Merck KGaA forecasts strong profit growth on healthcare, lab gear

    Merck KGaA said core earnings would see "strong" growth in 2020 when adjusted for one-offs and currency swings, but it would have to revise goals if the coronavirus outbreak does not start to ease from next month. "Should the crisis grow or trigger a global recession, the company would adapt its business forecast," it said in a statement.

  • Peter Thiel’s Palantir Wins Role in $823 Million Government Contract
    Bloomberg

    Peter Thiel’s Palantir Wins Role in $823 Million Government Contract

    (Bloomberg) -- Palantir Technologies Inc. scored another win in Washington Tuesday, securing a contract worth as much as $823 million to provide software to the Department of Defense, according to communications reviewed by Bloomberg.The four-year deal represents more than a decade of work by the Palo Alto, California-based data mining startup to break into the club of existing defense contractors, and bolsters the company’s prospects as it prepares it to go public.The contract is the second half of a larger project. Palantir and Raytheon Co. won the first half of the deal in 2018, worth $876 million. This second part involves Palantir working with BAE Systems to replace the U.S. Army’s Distributed Common Ground System, used for aggregating and analyzing data, which has faced technical challenges. Palantir sued the Army in 2016 to win the right to compete for the new contract after the U.S. Government Accountability Office determined the old system was underperforming and over budget. It is unclear how revenue from the contract will be split between Palantir and BAE Systems. The deal will increase annual sales at Palantir’s government division from its current $500 million or so, according to people familiar with Palantir’s finances who asked not to be identified discussing private information. Investor Peter Thiel co-founded Palantir in 2004, and the company’s software has been used for controversial ends like enabling the immigration deportation policies championed by President Trump, as well as for philanthropic ones like preventing sex trafficking and finding missing children.About half of Palantir’s business relies on deals with large corporate customers like Merck KGaA and Airbus SE,  which use the software to manage drug discovery and improve supply chain logistics.The company is exploring both an IPO and a direct listing, but does not yet have a target date for going public, Bloomberg has reported. To contact the author of this story: Lizette Chapman in San Francisco at lchapman19@bloomberg.netTo contact the editor responsible for this story: Anne VanderMey at avandermey@bloomberg.net, Alistair BarrFor more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • Pharma Stock Roundup: AZN Reports Q4 Results, NVS, PFE Drugs Get EU Approval
    Zacks

    Pharma Stock Roundup: AZN Reports Q4 Results, NVS, PFE Drugs Get EU Approval

    AstraZeneca's (AZN) Q4 results were disappointing. European Commission approves Novartis (NVS) and Pfizer's (PFE) new drugs.

  • Merck & Co., Inc. Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
    Simply Wall St.

    Merck & Co., Inc. Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

    The yearly results for Merck & Co., Inc. (NYSE:MRK) were released last week, making it a good time to revisit its...

  • Seattle Genetics (SGEN) Q4 Earnings Top, Adcetris Drives Sales
    Zacks

    Seattle Genetics (SGEN) Q4 Earnings Top, Adcetris Drives Sales

    Seattle Genetics (SGEN) rides high on Q4 earnings and revenue beat.

  • Pharma Stock Roundup: BMY, GSK, SNY Q4 Results, MRK Earnings & Split
    Zacks

    Pharma Stock Roundup: BMY, GSK, SNY Q4 Results, MRK Earnings & Split

    Merck (MRK), Bristol Myers (BMY), Sanofi (SNY), Glaxo (GSK) and Novo Nordisk (NVO) announce Q4 results.

  • Bristol-Myers' (BMY) Q4 Earnings & Revenues Beat Estimates
    Zacks

    Bristol-Myers' (BMY) Q4 Earnings & Revenues Beat Estimates

    Bristol-Myers (BMY) beats both earnings and sales estimates in the fourth quarter, primarily on robust sales of Eliquis and acquisition of Celgene.

  • Why Merck (MRK) is a Great Dividend Stock Right Now
    Zacks

    Why Merck (MRK) is a Great Dividend Stock Right Now

    Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.

  • Reuters - UK Focus

    US STOCKS-Wall St gains after strong US data, waning virus fears; Tesla limits Nasdaq's rise

    U.S. stocks rallied for a third straight day on Wednesday on encouraging U.S. economic data and waning fears of the financial fallout from a virus out of China but losses in Tesla shares pulled the Nasdaq off its record high. The ADP National Employment Report showed private payrolls jumped by 291,000 jobs in January, the most since May 2015, while a separate report showed U.S. services sector activity picked up in January, suggesting the economy could continue to grow moderately this year even as consumer spending is slowing. "There is at least not as much of a fear of an outcome of a pandemic that will have as much economic pressure globally as maybe initially was thought,” said Delores Rubin, senior equities trader at Deutsche Bank Wealth Management in New York.

  • Strong Private Sector Payrolls in January
    Zacks

    Strong Private Sector Payrolls in January

    Strong Private Sector Payrolls in January.

  • ADP Posts Blowout +291K New Jobs for January
    Zacks

    ADP Posts Blowout +291K New Jobs for January

    Monthly private-sector payrolls from Automatic Data Processing (ADP) for January posted their highest level this morning since May 2015, to a whopping 291K new private-sector jobs having been created.

  • Merck (MRK) Beats on Q4 Earnings, Plans Women Health Spin Off
    Zacks

    Merck (MRK) Beats on Q4 Earnings, Plans Women Health Spin Off

    Merck (MRK) beats estimates for earnings but misses the same for sales in fourth-quarter 2019. The company plans to spin off Women Health drugs/biosimilars into new company. Shares down.

  • Merck&Co Earnings Beat, Revenue Misses In Q4
    Investing.com

    Merck&Co Earnings Beat, Revenue Misses In Q4

    Investing.com - Merck&Co; reported on Wednesday fourth quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.

  • Peloton earnings, ADP jobs report: What to know in markets Wednesday
    Yahoo Finance

    Peloton earnings, ADP jobs report: What to know in markets Wednesday

    Private employment data and Peloton earnings will be in focus Wednesday.

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more